MedTrace Logo

Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy

NCT01708993 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2023-08-04

No results posted yet for this study

Summary

The purpose of this study is to find out if giving reolysin in combination with docetaxel or pemetrexed can offer better results than standard therapy with docetaxel or pemetrexed alone.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Pemetrexed and Reolysin (and safety run-in)

Pemetrexed: 500 mg/m², IV (10 min) - Day 1 every 3 weeks Reolysin: 4.5 x 10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks

DRUG

Pemetrexed

Pemetrexed: 500 mg/m² IV (10 min) - Day 1 every 3 weeks

DRUG

Docetaxel and Reolysin

Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks Reolysin: 4.5x10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks

DRUG

Docetaxel

Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks

Sponsors & Collaborators

Principal Investigators

  • Donald G Morris · Tom Baker Cancer Centre, Calgary Alberta Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-10
Primary Completion
2016-01-26
Completion
2018-09-26

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01708993 on ClinicalTrials.gov